Torren Management’s ArriVent BioPharma AVBP Stock Holding History

Torren Management’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15K	Hold	33	–	–	﹤0.01%	711
2026 Q1	$761	Hold	33	–	–	﹤0.01%	797
2025 Q4	$664	Buy	+33	New	+$687	﹤0.01%	1284

Other funds holding AVBP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

Torren Management's AVBP Position: Q2 2026 in Review

Torren Management held its ArriVent BioPharma (AVBP) position steady in Q2 2026 at 33 shares worth $1.15K. The position accounts for ﹤0.01% of the portfolio, ranked #711.

Torren Management first reported a position in AVBP in Q4 2025 and has held it in 3 quarters since. 41 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

Torren Management held 33 shares of ArriVent BioPharma worth $1.15K as of Q2 2026.
Torren Management left its ArriVent BioPharma share count unchanged in Q2 2026.
ArriVent BioPharma made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #711 holding.
Torren Management first reported a position in ArriVent BioPharma in Q4 2025 and has held it in 3 quarters since.
41 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.